Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.

× No keyword cloud information.

23 in total

1. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors: Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal: Hepatology Date: 2011-12-16 Impact factor: 17.425

2. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors: Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal: J Biol Chem Date: 2011-10-14 Impact factor: 5.157

3. Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.

Authors: Madeline Odigie; Anu Osinusi; Lisa Barrett; Kerry Townsend; Honghui Wang; Anthony F Suffredini; Henry Masur; Michael A Polis; Shyam Kottilil
Journal: AIDS Res Hum Retroviruses Date: 2014-06-30 Impact factor: 2.205

4. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Authors: April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens
Journal: J Med Virol Date: 2012-09 Impact factor: 2.327

5. Access to care for vulnerable veterans with hepatitis C: a hybrid conceptual framework and a case study to guide translation.

Authors: Catherine Rongey; Steven Asch; Sara J Knight
Journal: Transl Behav Med Date: 2011-12 Impact factor: 3.046

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.

1. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

2. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

3. Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.

4. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

5. Access to care for vulnerable veterans with hepatitis C: a hybrid conceptual framework and a case study to guide translation.

6. Griffithsin has antiviral activity against hepatitis C virus.

Review 7. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials.

8. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.

Review 9. Therapeutic development in targeting protein-protein interactions with synthetic topological mimetics.

10. Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405.